Nutra Pharma Announces Launch of Equine Nyloxin(R) for Use in Horses
October 30 2013 - 8:00AM
Marketwired
Nutra Pharma Announces Launch of Equine Nyloxin(R) for Use in
Horses
Nutra Pharma Is Announcing the Launch of Their New Homeopathic
Formula for the Treatment of Chronic Pain and Inflammation in
Horses, Equine Nyloxin(R)
CORAL SPRINGS, FL--(Marketwired - Oct 30, 2013) - Nutra Pharma
Corporation (OTCQB: NPHC), a biotechnology company that is
developing treatments for Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain,
announced today that they are in the process of launching the
newest addition to their line of homeopathic treatments for chronic
pain, Equine Nyloxin®.
Equine Nyloxin® is a topical therapy for
horses that is packaged as a two piece kit: Nyloxin® Topical
Gel comprises Step 1 and a solution of DMSO
(dimethylsulfoxide) comprises Step 2. Specialized proteins in
Nyloxin® block the action of acetylcholine, a major stimulating
neurotransmitter in the nervous system and activator of the
inflammatory pathways. As a result, the pain and inflammation
pathways are temporarily shut off. DMSO has long been used
topically in horses to reduce swelling and inflammation associated
with strained muscles and soft tissue injuries. The DMSO also
greatly enhances the uptake of the Nyloxin peptides into the
joints.
"We've been using Nyloxin with horses for a few years with great
results," commented Rik J Deitsch, CEO of Nutra Pharma Corporation.
"Recently we were approached by horse trainers that requested a
product specifically formulated for use with equines. Since DMSO is
already accepted and utilized by many trainers, it was easy to
create this new approach to marry a DMSO gel formulation with our
Nyloxin Topical Gel," he continued. "We've been working with
trainers and veterinarians in the equine industry and have already
identified distributors for the Equine Nyloxin®,"
he concluded.
According to The America Horse Council Foundation, there are
over 9.2 million horses in the United States with more than 2
million people that own horses. The horse industry has a direct
economic effect on the U.S. of $39 billion annually. Additionally,
there are horses in every state and Forty-five states have at least
20,000 horses each.
Recently, Nutra Pharma announced the launch of Pet
Pain-Away, an oral formulation for the treatment of moderate
to severe chronic pain in companion animals. The Equine
Nyloxin® represents the Company's first topical
solution for the animal market. Nutra Pharma expects to have the
product available in the first quarter of 2014.
About Nutra Pharma Corp. Nutra Pharma Corporation operates as a
biotechnology company specializing in the acquisition, licensing,
and commercialization of pharmaceutical products and technologies
for the management of neurological disorders, cancer, autoimmune,
and infectious diseases, including Multiple Sclerosis (MS), Human
Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain.
The Company markets several drug products for sale for the
treatment of pain under the brands Cobroxin® and Nyloxin®. For
additional information about Nutra Pharma, visit:
www.NutraPharma.com or www.Nyloxin.com
SEC Disclaimer This press release contains forward-looking
statements. The words or phrases "would be," "will allow," "intends
to," "will likely result," "are expected to," "will continue," "is
anticipated," "estimate," "project," or similar expressions are
intended to identify "forward-looking statements." Actual results
could differ materially from those projected in Nutra Pharma's
("the Company") business plan. The launch of Equine Nyloxin should
not be construed as an indication in any way whatsoever of the
future value of the Company's common stock or its present or future
financial condition. The Company's filings may be accessed at the
SEC's Edgar system at www.sec.gov. Statements made herein are
as of the date of this press release and should not be relied upon
as of any subsequent date. The Company cautions readers not to
place reliance on such statements. Unless otherwise required by
applicable law, we do not undertake, and we specifically disclaim
any obligation, to update any forward-looking statements to reflect
occurrences, developments, unanticipated events or circumstances
after the date of such statement.
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nutra Pharma (CE) (USOTC:NPHC)
Historical Stock Chart
From Sep 2023 to Sep 2024